文献速递乳腺癌

MTClin整合MammaTyper预测HER2阳性乳腺癌新辅助治疗反应

MTClin: Integrating MammaTyper® to predict neoadjuvant therapy response in HER2+ breast cancer.
PubMed 文献 · Eur J Cancer · 2025-10-18

本研究评估CE/IVD MammaTyper试剂盒预测HER2阳性早期乳腺癌新辅助治疗反应。154例治疗前空芯针活检样本经RT-qPCR检测四个基因mRNA,结合肿瘤大小和淋巴结状态构建决策树模型MTClin。模型在HR+和HR-肿瘤中均显示较高敏感性和特异性,并可预测3年和5年复发风险。

要点

  • MTClin模型在HR+肿瘤中预测pCR的敏感性90.2%、特异性86.8%。
  • HR-肿瘤中敏感性96%、特异性88%,cT1N0 HR-亚组敏感性和NPV最高。
  • 复发预测3年AUC 0.98、5年AUC 0.96,支持治疗升阶或降阶。

核心结论

  • MTClin可能预测HER2阳性乳腺癌的pCR和复发,支持个体化治疗调整。

研究设计与样本

  • 研究纳入161例接受曲妥珠单抗为基础新辅助治疗的HER2阳性(IHC 3+)浸润性乳腺癌患者,排除7例后对154例FFPE治疗前空芯针活检样本进行检测,其中HR+ 79例、HR- 75例。
  • 采用MammaTyper®(RT-qPCR体外诊断试剂)评估ERBB2、ESR1、PGR、MKI67 mRNA水平,使用Python决策树算法结合四个基因的ΔΔCq值、肿瘤大小和淋巴结状态构建MTClin模型。
  • 模型在cT1N0亚组中进一步应用,并预测3年和5年复发风险;超参数通过GridSearchCV结合5折交叉验证调优,性能指标包括敏感性、特异性、PPV和NPV。

主要发现

  • 154例中91例达到pCR,63例达到病理部分缓解(pPR)。
  • 在HR+肿瘤中,模型预测pCR的敏感性90.2%、特异性86.8%、PPV 88.1%、NPV 89.2%。
  • 在HR-肿瘤中,敏感性96%、特异性88%、PPV 94.1%、NPV 91.7%。
  • cT1N0 HR-亚组的敏感性和NPV最高。
  • 复发预测的AUC在3年时为0.98,5年时为0.96。

临床怎么用

  • MTClin模型可用于HER2阳性乳腺癌新辅助治疗前预测pCR,辅助识别可能受益于治疗升阶或降阶的患者。
  • 模型还可预测3年和5年复发风险,为随访和治疗策略提供参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: Neoadjuvant therapy (NAT) is the standard of care for most HER2-positive early breast cancer (BC). However, 25 to 50% of patients fail to achieve a pathological complete response (pCR). This study evaluates the CE/IVD MammaTyper® kit (Cerca Biotech) as a predictor of response in this setting. METHODS: A total of 161 HER2-positive (IHC score 3+) invasive BC patients treated with trastuzumab-based NAT were enrolled. After excluding seven cases (insufficient RNA amount or dual anti-HER2 blockade), 154 FFPE preoperatory core-biopsies were tested: 79 hormone-positive (HR+) and 75 hormone-negative (HR-). Ninety-one achieved a pCR, 63 attained a pathological partial response (pPR). MammaTyper®, an in vitro diagnostic RT-qPCR test, assessed ERBB2, ESR1, PGR, MKI67 mRNA levels. A Python-based Decision Tree Algorithm was used to predict pCR using ΔΔCq values of the four genes alongside tumor size and nodal status (MTClin). The model was further applied to a cT1N0 subgroup and to predict the recurrence risk at 3 and 5 years. Hyperparameters were tuned using GridSearchCV with a 5-fold cross-validation. Performance metrics included sensitivity, specificity, PPV and NPV. RESULTS: Two decision trees were selected for optimal accuracy. In HR+ tumors, the model yielded 90.2 % sensitivity, 86.8 % specificity, 88.1 % PPV and 89.2 % NPV. In HR- tumors, sensitivity was 96 %, specificity 88 %, PPV 94.1 %, and NPV 91.7 %. Sensitivity and NPV were highest in the cT1N0 HR- subgroup. Recurrence prediction yielded AUCs of 0.98 (3 years) and 0.96 (5 years). CONCLUSIONS: MTClin may predict pCR and recurrence in HER2-positive BC, supporting tailored escalation or de-escalation treatment.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Belcastro E, Marletta S, Tornabene I, et al. MTClin: Integrating MammaTyper® to predict neoadjuvant therapy response in HER2+ breast cancer. Eur J Cancer. 2025. PMID: 41138351. doi:10.1016/j.ejca.2025.116049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。